Biotech Values

[dav1234]

Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically
Tools Email
Print
Contact Author

Posted January 18, 2012

Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapies

Pivotal trial data to be presented for the first time at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI)



Read more: Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically - FierceBiotech http://www.fiercebiotech.com/press-releases/phase-iii-data-show-bayers-investigational-compound-regorafenib-bay-73-4506#ixzz1jsOZoc1W
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech